Ocugen is trading 12.4% down at $1.17 after no clear company-specific catalyst was identified for September 9, 2026.
- Ocugen is scheduled to present its modifier gene therapy platform at the Citi 2026 Biopharma Back to School Conference from 3:40–4:15 p.m. ET; the event was announced previously and is not evidence of a negative development.
- Major U.S. indexes are down modestly, offering limited broader-market context.